



### Company Overview

Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.

### Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration

Feb 28 2025, 4:05 PM EST

### Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

Nov 12 2024, 4:30 PM EST

### Stock Overview

**Symbol** SYRS  
**Exchange** Nasdaq  
**Market Cap** 692.28k  
**Last Price** \$0.0258  
**52-Week Range** \$0.0215 - \$6.9275

### Investor Relations

Syros Pharmaceuticals  
[ir@syros.com](mailto:ir@syros.com)  
Transfer Agent  
Computershare Trust Company,  
N.A.

04/01/2025 07:58 PM EDT

### Management Team

#### Gerald E. Quirk

CEO and President

### Syros Pharmaceuticals, Inc.

35 CambridgePark Drive  
4th Floor  
Cambridge, MA 02140

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.